Dilated cardiomyopathy and role of antithrombotic therapy

American Journal of the Medical Sciences

Volumn 339, Issue 6, 2010, Pages 557-560

  Abdo, Ashraf S ^a   Kemp, Rhonda ^b   Barham, Jennifer ^b   Geraci, Stephen A ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Antithrombotic therapy; Cardiomyopathy

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DEFIBRILLATION; DISEASE ASSOCIATION; DRESSLER SYNDROME; DRUG EFFICACY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERTENSION; PREVALENCE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 77953345376     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181cf048a     Document Type: Review

References (39)

1. Chesebro JH, Ezekowitz M, Badimon L, et al. Intracardiac thrombi and systemic thromboembolism: detection, incidence, and treatment. Annu Rev Med 1985;36:579-605
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952
3. Padanilam BJ, Prystowsky EN. Atrial fibrillation: goals of therapy and management strategies to achieve the goals. Cardiol Clin 2009;27: 189-200
4. Lip GY, Gibbs CR. Anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2001;(4):CD003336
5. De Lorenzo F, Saba N, Kakkar VV. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. Drugs 2003;63:565-576
6. Patanè S, Marte FA. Large left ventricular thrombus. Int J Cardiol 2009;135:44-46
7. Elkayam U, Khan S, Mehboob A, et al. Impaired endotheliummediated vasodilation in heart failure: clinical evidence and the potential for therapy. J Card Fail 2002;8:15-20
8. Mazzone M, La Sala M, Portale G, et al. Review of dilated cardiomyopathies. Dilated cardiomyopathies and altered prothrombotic state: a point of view of the literature. Panminerva Med 2005;47:157-167
9. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14: 205-212
10. Ahnert AM, Freudenberger RS. What do we know about anticoagulation in patients with heart failure? Curr Opin Cardiol 2008;23: 228-232
11. Chong AY, Freestone B, Patel J, et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006;97:671-675
12. Jessup M, Abraham WT, Casey DE, et al. Focused update: ACCF/ AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016
13. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(suppl 6):630S-9S
14. Ringleb PA, Bousser MG, Ford G, et al. Guidelines for management of ischemic stroke and transient ischemic attack 2008. Cerebrovasc Dis 2008;25:457-507
15. Sirajuddin RA, Miller AB, Geraci SA. Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: a critical literature review. J Card Fail 2002;8:48-53
16. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810-815
17. Spodick DH, Littmann D. Idiopathic myocardial hypertrophy. Am J Cardiol 1958;1:610-623
18. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993;126:141-146
19. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983;250:2942-2946
20. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(suppl 6):VI94 -101
21. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the Studies of Left Ventricular Dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080
22. Kenchaiah S, Davis BR, Braunwald E, et al. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: insights from the Survival and Ventricular Enlargement Trial. Am Heart J 2004;148:356-364
23. Loh E, Sutton MS. Anticoagulation and left ventricular dysfunction: friend or foe? Eur Heart J 1997;18:1039-1041
24. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257
25. Hays AG, Sacco RL, Rundek T, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006;37:1715-1719
26. Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007;115:2637-2641
27. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-164
28. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:101-112
29. Cokkinos DV, Haralabopoulos GC, Kostis JB, et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;8:428-432
30. Holmes Jr DR, Kereiakes DJ, Kleiman NS, et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009;54:95-109
31. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147:463-467
32. Griffith GC, Stragnell R, Levinson DC, et al. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952;37:867-887
33. Gibelin P. Anticoagulant treatment and dilated cardiomyopathy. Arch Mal Coeur Vaiss 1995;88(suppl 4):617-621
34. Lip GY, Gibbs CR. Anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2001;(4):CD003336
35. Petitti DB, Storm BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989;42:759-764
36. Graham SP. Anticoagulation and heart failure. Curr Cardiol Rep 2001;3:72-77
37. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-250
38. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562
39. Pullicino P, Thompson JL, Barton B, et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006;12:39-46